The landscape of novel therapeutics and challenges in glioblastoma multiforme: Contemporary state and future directions by Khaddour, Karam et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2020 
The landscape of novel therapeutics and challenges in 
glioblastoma multiforme: Contemporary state and future 
directions 
Karam Khaddour 
Tanner M Johanns 
George Ansstas 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
pharmaceuticals
Review
The Landscape of Novel Therapeutics and Challenges
in Glioblastoma Multiforme: Contemporary State
and Future Directions
Karam Khaddour 1,2,* , Tanner M. Johanns 2 and George Ansstas 2,*
1 Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA
2 Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO 63110, USA;
tannerjohanns@wustl.edu
* Correspondence: karam.khaddour@gmail.com (K.K.); gansstas@wustl.edu (G.A.);
Tel.: +1-314-362-5677 (G.A.)
Received: 27 October 2020; Accepted: 12 November 2020; Published: 14 November 2020 
Abstract: Background: Glioblastoma multiforme is a malignant intracranial neoplasm that constitutes
a therapeutic challenge because of the associated high morbidity and mortality given the lack
of effective approved medication and aggressive nature of the tumor. However, there has been
extensive research recently to address the reasons implicated in the resistant nature of the tumor to
pharmaceutical compounds, which have resulted in several clinical trials investigating promising
treatment approaches. Methods: We reviewed literature published since 2010 from PUBMED and
several annual meeting abstracts through 15 September 2020. Selected articles included those relevant
to topics of glioblastoma tumor biology, original basic research, clinical trials, seminal reviews,
and meta-analyses. We provide a discussion based on the collected evidence regarding the challenging
factors encountered during treatment, and we highlighted the relevant trials of novel therapies
including immunotherapy and targeted medication. Results: Selected literature revealed four
main factors implicated in the low efficacy encountered with investigational treatments which
included: (1) blood-brain barrier; (2) immunosuppressive microenvironment; (3) genetic heterogeneity;
(4) external factors related to previous systemic treatment that can modulate tumor microenvironment.
Investigational therapies discussed in this review were classified as immunotherapy and targeted
therapy. Immunotherapy included: (1) immune checkpoint inhibitors; (2) adoptive cell transfer therapy;
(3) therapeutic vaccines; (4) oncolytic virus therapy. Targeted therapy included tyrosine kinase inhibitors
and other receptor inhibitors. Finally, we provide our perspective on future directions in treatment
of glioblastoma. Conclusion: Despite the limited success in development of effective therapeutics
in glioblastoma, many treatment approaches hold potential promise including immunotherapy and
novel combinational drugs. Addressing the molecular landscape and resistant immunosuppressive
nature of glioblastoma are imperative in further development of effective treatments.
Keywords: glioblastoma multiforme; immunotherapy; immune checkpoint inhibitors; vaccine; CART
therapy; oncolytic virus; immunosuppressive
1. Introduction
Glioblastoma multiforme is the most aggressive intracranial tumor; histologically considered as
a malignant glioma arising from an astrocytic lineage (WHO classification: astrocytoma grade IV),
and it represents the most common malignant primary brain tumor in adults [1,2]. Despite the low
incidence rate of glioblastoma compared to other cancer types, it portends an extremely poor prognosis
with a median overall survival (OS) of approximately 1 year, and a relative survival rate at 5 and 10 years
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approximately (5% and 3%, respectively) [3,4]. Glioblastoma is considered a privileged tumor because
of its isolation from the surrounding structures, and the presence of the blood brain barrier (BBB) which
impedes the passage of several immune cells and chemotherapeutics [5]. In addition, the heterogeneous
genetic and molecular landscape of glioblastoma constitutes a challenge in the face of developing
effective therapies, which is reflected by the lack of drug approval in the past decade [6]. The cornerstone
of glioblastoma management relies on maximal surgical resection of the tumor with concurrent
chemoradiation using the alkylating agent temozolomide (TMZ) followed by adjuvant TMZ for a total
of 6 months according to the landmark trial by Stupp et al. [7]. The other treatment modality that has
shown improved OS in glioblastoma patients is the addition of tumor treating field (TTF) to the current
standard of care (Stupp protocol), which is a device worn by the patient on the scalp, and works by
delivering alternating electrical fields that disrupt the microtubules in the mitotic spindle leading to
tumor cell death [8]. However, this treatment has proved to be challenging for patients given the
low compliance rates with its use and high cost [9]. The addition of bevacizumab which is a vascular
endothelial growth factor (VEGF) inhibitor, in newly diagnosed and recurrent glioblastoma-selected
patients demonstrated modest improvement in progression-free survival (PFS) and better quality of
life, but was associated with a high rate of adverse events without an improvement in OS [10–12].
As the majority of glioblastoma ultimately recur during or after treatment, it is imperative to develop
therapeutic drugs that could offer clinical benefit to these patients to improve survival, and decrease
disease associated morbidity and complications. This unmet need has led to extensive preclinical
research to further characterize the molecular and genetic alterations that control tumor growth,
as well as the interaction between the immune system and glioblastoma in order to identify candidate
targets for effective drug development. This comprehensive effort in the last decade has substantially
expanded our understanding of glioblastoma and has been previously reviewed in depth [13,14].
Nevertheless, the limited drug approval for glioblastoma relative to the novel investigational therapies
that have been tested, and the modest improvement in OS achieved in the past decade demonstrate
the obligation for further research in the field of neuro-oncology to develop new therapies that can
improve patient outcomes as outlined in Figure 1. Recently, there have been promising novel drugs
including targeted molecular therapy and immunotherapy that have established a possible role in
anti-tumor response in glioblastoma. Moreover, enhanced drug delivery across BBB and combination
treatment modalities seem to hold a prospective role in the treatment of glioblastoma.
In this review, we discuss the distinct factors that are essential in understanding the challenges
in the treatment of glioblastoma. Second, we offer a review of potential novel treatments including
(immunotherapy and targeted therapy), and the rationale behind their use. Finally, we present our
prospective on future directions in the pursuit of novel effective treatments for glioblastoma.
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Figure 1. Timeline of treatment approval for glioblastoma and landmark investigational non-
approved drugs. The lower panel demonstrates Kaplan–Meier curves of three pivotal randomized 
controlled trials in newly diagnosed glioblastoma which led to the approval of standard of care 
systemic treatment including concurrent radiation and temozolomide (Stupp protocol) [7], addition 
of bevacizumab to Stupp protocol [10,11], and use of tumor-treating fields with Stupp protocol [8]. 
Despite the improvement of OS with the addition of temzolomide, bevacizumab and TTF, the overall 
survival remains poor (as noted by the continued drop in slope of the curves). There are no approved 
treatments shown to improve the survival in recurrent glioblastoma (not shown in this figure) [12]. 
Kaplan–Meier curves reprinted by permission from the Massachusetts Medical Society (NEJM) and 
American Medical Association (JAMA). N Engl J Med. Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn 
MJ, Belanger K et al., copyright © 2005. N Engl J Med. A randomized trial of bevacizumab for newly 
diagnosed glioblastoma. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum 
MA et al., copyright © 2014. JAMA. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide 
vs. Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized 
Clinical Trial. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B et al., copyright © 
2017. Abbreviations: TMZ: temozolomide, mOS: median overall survival, mPFS: median progression 
free survival, RT: radiation therapy, SOC: standard of care, TTF: tumor-treating fields. 
In this review, we discuss the distinct factors that are essential in understanding the challenges 
in the treatment of glioblastoma. Second, we offer a review of potential novel treatments including 
(immunotherapy and targeted therapy), and the rationale behind their use. Finally, we present our 
prospective on future directions in the pursuit of novel effective treatments for glioblastoma. 
2. Exploiting the Blood-Brain Barrier and the Immune System against Glioblastoma: The Wrong 
Notion of the Immune Desert in Glioblastoma 
Perhaps the most consequential discovery that has shifted the paradigm of cancer treatment and 
substantially led to improved outcomes in multiple cancer types is the discovery of the immune 
system role in preventing tumor growth and killing cancer cells which has coined the term “anti-
tumor immunity” [15]. For example, checkpoint receptors are membrane-bound proteins that are 
found on malignant cells as well as immune cells such as T-cell subsets, natural killer (NK) cells, 
antigen presenting cells (APC) including macrophages and dendritic cells. These checkpoint 
receptors, are usually upregulated and highly expressed in the tumor microenvironment (TME) of 
several tumor types, and when bound to their respective ligands are responsible for negative 
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2. Exploiting the Blood-Brain Barrier and the Immune System against Glioblastoma: The Wrong
Notion of the Immune Desert in Glioblastoma
Perhaps the most consequential discovery that has shifted the paradigm of cancer treatment
and substantially led to improved outcomes in multiple cancer types is the discovery of the immune
system role preventing tumor growth killing cancer cells which has coined the term “anti-tumor
immunity” [15]. For example, checkp int receptors are membrane-bound proteins that are found on
malignant cells as well as immune cells such as T-cell subsets, natural killer (NK) cells, antigen presenting
cells (APC) including macrophages and dendritic cells. These checkpoint receptors, are usually
upregulated and highly expressed in the tumor microenvironment (TME) of several tumor types,
and when bound to their respective ligands are responsible for negative regulation of immune cells
leading to increased immune evasion by the tumor through the disruption of innate and adaptive
anti-tumor functio [16–18]. This has resulted in the development of several monoclonal antibodies
dir ted at checkpoint receptors such as cytoto ic-a ociated lymphocyte a tige -4 (CTLA-4) and
programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) [19]. This class of m dication
known as immune checkpoint inhibitor (ICI) has demonstrated a significant prolonged PFS and
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OS in several tumors including melanoma, lung, genitourinary, liver, and breast cancers [20–27].
Other checkpoint inhibitors are currently being investigated such as inhibitors of T-cell immunoglobulin
and mucin-domain containing-3 (TIM3), lymphocyte activation gene-3 (LAG3), and indoleamine
2,3-dioxygenase-1 (IDO1) [28,29]. Another example that demonstrated the utility of immune derived
cells in the treatment of cancer was the use of bioengineered chimeric antigen receptor loaded
on autologous T-cells (CAR-T), which have shown efficacy and improved outcomes in relapsed
acute lymphoblastic leukemia, refractory diffuse large-B cell lymphoma (DLBCL), and relapsed
follicular lymphoma [30,31]. Moreover, the efficacy of oncolytic virus therapy such as talimogene
laherparevec (TVEC) in melanoma and autologous dendritic vaccination therapy in prostate cancer
have further extended the advent of immunotherapy in the treatment of cancer [32,33]. As such,
several immunotherapies that recruit the immune system against cancer cells have been investigated
in different tumor types including glioblastoma. To this end, glioblastoma has been regarded for
a long time as an isolated tumor encased by BBB, which makes it devoid of active immune cells.
This notion has been abandoned in the past decade after several preclinical and clinical studies
demonstrated the role of the immune system in the TME of intracranial tumors including glioblastoma.
Comprehensive analysis of the role of the immune system in glioblastoma is out of the scope of this
review and has been summarized in detail elsewhere [14,34]. To better explain the current challenges in
implementing effective immunotherapies for glioblastoma, it is imperative to understand the cross-talk
between malignant cells of glioblastoma and immune cells and the immunosuppressive nature of the
tumor. Several factors govern this interaction, and can be classified into the following: (1) factors
related to BBB; (2) factors related to the immunosuppressive microenvironment; (3) factors related to
tumor heterogeneity and genetic signature of glioblastoma subtypes; and (4) extrinsic factors related to
the modulating effect of previous systemic treatment.
2.1. Factors Related to BBB
The blood-brain barrier (BBB) forms a dynamic interaction of endothelial cells, pericytes, microglia,
astrocytes, and is responsible for the integrity of the central nervous system [35]. BBB plays an essential
role in regulating the passage of water, ions, immune cells, nutrients, and therapeutic drugs through its
complex physical barrier manifested by tight junctions and enzymatic–metabolic pathways that control
transportation of different molecules. This can hinder the delivery of therapeutic drugs into the brain
compartment as it is estimated that BBB restricts the penetration of 98% of small molecules and 100% of
large molecules [36]. In glioblastoma, the integrity of the BBB is disrupted, which leads to alterations
involving the vascular bed. The aggressive nature of glioblastoma leads to invasion of endothelial
cells and breakage of tight junctions which results in a breach in the BBB [37,38]. Nevertheless,
this disruption is not sufficient to allow increased concentration of therapeutic compounds in the tumor
bed. Moreover, glioblastoma invasion into the surrounding structures is associated with angiogenesis
because of hypoxia-induced VEGF formation, which though could potentially increase drug availability
via the tumor vasculature, it also leads to pathological alterations in the BBB and suboptimal drug
concentration in tumor foci outside the disrupted region [39]. The constellation of pathophysiological
alterations in the vasculature bed associated with glioblastoma has coined the term blood-brain tumor
barrier (BBTB) because of its unique features compared to BBB. To this end, analyzing the structure
and changes associated with BBTB can aid in effective treatment development for glioblastoma and is
an area for active research [40].
Of importance to immunotherapy, BBB plays an essential role in regulating immunosurveillance
and restricting immune cell passage into the central nervous system (CNS), which could limit the
efficacy of many novel drugs that work by recruiting the immune system to attack cancer cells.
However, the insight gained from other CNS diseases on the ability of immune cells to cross BBB
in certain autoimmune and inflammatory diseases, could help further research on exploiting this
vulnerability in the administration of novel immunotherapies in glioblastoma [41–43].
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To circumvent these challenges, several methods are under ongoing investigation to overcome
the BBB and BBTB and achieve sufficient delivery of therapeutic compounds inside glioblastoma.
One promising method is the delivery of drugs through nanoparticles which allow for the individual
units loaded with drug to be carried to glioblastoma cells [44]. For example, nano-immunoconjugates
(anti CTLA-4 and anti PD-1) on natural biopolymer scaffold were able to induce immune response
in glioma cells and lead to a significant prolonged survival in mice with intracranial GL261
glioblastoma [45]. Similarly, another group of investigators showed that the delivery of small
interfering RNAs (siRNA) against both epidermal growth factor receptor (EGFR) and PD-L1 through
solid lipid nanoparticles in glioblastoma mouse models, was able to decrease the growth of glioblastoma
and prolong mouse survival [46].
Convection-enhanced delivery (CED) is another promising method that has shown to encourage
preclinical and clinical results [47]. This method relies on establishing a pressure gradient during
interstitial infusion of the pharmaceutical compound to augment its distribution into the intracranial
tumor to achieve enhanced local drug delivery. One recent example of the clinical benefit associated
with CED is the work by Desjardins et al. that showed mild increased OS in patients with
recurrent glioblastoma who received intertumoral recombinant nonpathogenic polio-rhinovirus chimera
(PVSRIPO) versus matching historical control (median OS 12.5 months vs. 11.3 months, respectively) [48].
Nevertheless, further research is essential to evaluate the safety and efficacy of CED to better identify
the best drugs to use with this method as well as unifying treatment protocols and ascertaining the
delivery of the infused molecule into tumor bed.
Moreover, it is important to note that some drugs can have an effect on glioblastoma despite not
being able to penetrate BBB into the tumor. For example, bevacizumab, which is a VEGF inhibitor
that has shown improved PFS and quality of life in glioblastoma patients, prevents angiogenesis
within the vasculature compartment without the need of being present inside the tumor cells [10–12].
Another example is the use of ICI that can restore anti-tumor efficacy by blocking checkpoint
receptors present not only in the tumor milieu, but also in the benign peripheral lymphatic system [49].
This warrants further investigation on novel treatments that could have a potential effect on glioblastoma
without the need to penetrate BBB.
2.2. Factors Related to Glioblastoma Immunosuppressive Microenvironment
The long-standing historical notion of the CNS being considered an immune desert because it is
devoid of effective resident immune cells has been challenged by rigorous research which demonstrated
that the CNS has specific lymphatic system and is occupied by immune cells with unique characteristics
compared to its counterparts in other organs [50].
The paramount advances in cancer treatment with the introduction of ICI as well as other
immunotherapies have drastically shifted the focus in cancer treatment on exploiting pathways
involved in host immune defense mechanisms to fight cancer cells “anti-tumor immunity.”
Although immunotherapies have shown significantly improved outcomes in different solid
and hematological malignancies, the outcomes in glioblastoma have been mild to moderate at best.
This stems from the fact that TME of glioblastoma employs an immunosuppressive effect despite
the abundance of a variety of immune cell subsets [14,51]. For example, despite the presence of
a functional lymphatic system in the CNS that provides the potential for tumor antigen to prime
cognate T cells that could mediate anti-tumor immunity, glioblastoma exerts an inhibitory effect
on the functionality of T cells through several mechanisms [52,53]. Moreover, glioblastoma can
disrupt the function of non-resident T cells beyond the tumor bed and can affect potential effective
peripheral T-cell populations and lead to their entrapment in the bone marrow because of the loss
of spingosine-1-phosphate receptor 1 (S1P1) [54]. By contrast, glioblastoma allows the expansion of
specific T-cell subsets such as T-regulatory (Treg) cells which are responsible for immune tolerance and
promotion of tumor growth [55]. In addition, natural killer (NK) cells which are innate-like immune
cells equipped with potent cytotoxic activity against tumor cells are suppressed in glioblastoma [56].
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Additionally, tumor-associated macrophages (TAM) and microglia are essential subtypes of
immune cells that constitute the majority of cellular mass in glioblastoma (30–50%) [57]. These cells are
considered antigen presenting cells (APC) and are responsible for the presentation of tumor-associated
antigens to be recognized by effector T cells [57]. TAMs constitute the majority of APC in glioblastoma
while microglia account for an additional 15% of APCs [58,59]. Both TAMs and microglia are implicated
in gliomagenesis in glioblastoma through several mechanisms including immune suppression and
secretion of several soluble factors such as transforming growth factor-β (TGF-β) and interleukin-10
(IL-10) that can further exacerbate immunosuppressive state [60–62]. Furthermore, antigen presentation
processes are impaired in glioblastoma because of impaired upregulation of major histocompatibility
complex (MHC) class II [63].
The other important factor that is associated with an immunosuppressive microenvironment in
glioblastoma is the increased expression of checkpoint receptors such as PD-L1, IDO, TIM3 on T-cells
and TAMs [64–70]. Similarly, glioblastoma favors the expression of several inhibitory molecules such
as signal transducer and activator of transcription 3 (STAT3) and Fas ligand (FasL) which aggravate
immune inhibitory signals and promote T-cell apoptosis, respectively [71,72].
For the abovementioned reasons, the negative impact of glioblastoma on the immune
microenvironment which favors the presence of dysfunctional and deregulated immune cell
subpopulations, constitute a major challenge on the implementation of effective immunotherapies in
the treatment of glioblastoma. Therefore, efforts are focused on exploiting existing vulnerabilities in the
TME of glioblastoma to reactivate the immune system against tumor cells. For example, TAMs display
plasticity which refers to their ability of switching their phenotypic features leading to a change in
their function. As such, this plasticity could be exploited to selectively express a phenotype that
favors macrophage type-1 (M1) which is a pro-inflammatory cell that can boost host immunity versus
macrophage type-2 (M2) which is considered pro-tumorigenic [73]. Similarly, the increased expression
of checkpoint receptors in TME of glioblastoma can be targeted with the use of combinational ICI to
rescue effector T-cells and to restore immune surveillance in glioblastoma.
2.3. Factors Related to Tumor Heterogeneity and Genetic Signature of Glioblastoma Subtypes
The common definition of glioblastoma by World Health Organization classification as a high-grade
glioma-IV offers limited insight into the genetic heterogeneity of glioblastoma. Genomic characterization
by The Cancer Genome Atlas (TCGA) research group and the comprehensive molecular analysis helped
delineate three distinct tumor-intrinsic transcriptional glioblastoma subtypes including proneural,
mesenchymal, and classical [74,75]. This classification relies on the predominant genetic signature
associated with each subtype. For example, while the proneural subtype of glioblastoma is associated
with amplification in platelet-derived growth factor receptor alpha (PDGFRA), the mesenchymal
subtype can be associated with alteration in neurofibromatosis type 1 (NF1), and classical subtype is
associated with amplification in EGFR [76]. This is of interest given the evidence that specific expression
patterns due to amplification in PDFGRA and EGFR could serve as prognostic biomarkers [77,78].
In addition, some specific immune cell types such as TAM have been shown to have higher expression
of their related genes in the mesenchymal subtype of glioblastoma [79].
The genetic heterogeneity appears to reflect distinct glioblastoma immune subsets based on the
molecular signature [80]. For example, glioblastoma with wild-type isocitrate dehydrogenase (IDH)
status is associated with a higher tumor infiltrative lymphocyte (TIL) and higher PD-L1 expression
compared to IDH mutated glioblastoma [81]. Similarly, there is an increased PD-L1 expression on
both resident T cells and circulating monocytes in glioblastoma with PTEN loss [82]. In addition,
the glioblastoma mesenchymal subtype that is associated with NF-1 and RB-1 mutations can have
significantly increased TIL [83]. This suggests that specific genetic alterations can be associated with
an abundance of immune cells and increased expression of checkpoint receptors which could help select
subgroups of glioblastoma patients who could derive a better response to immunotherapy. However,
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clinical correlation is still lacking with some evidence showing no predictive value of increased TIL or
checkpoint receptors in glioblastoma subsets with improved response to ICI [84].
Furthermore, tumor mutation burden (TMB) status that estimates the frequency of mutations
that are present per megabase of malignant cell DNA correlates with response observed in several
solid malignancies during treatment with ICI. This is the result of increased neoantigen formation
and presence of new mutant proteins that are immunogenic and can induce anti-tumor response [85].
As such, glioblastoma patients with high TMB could reflect a subpopulation that can have better
response to immunotherapies such as ICI compared to glioblastoma patients with low TMB. This is of
importance given that glioblastoma patients have low TMB at baseline which can limit anti-tumor
immunity and explain weak response to immunotherapy [86]. Interestingly, there is a subset of patients
with glioblastoma that can have hypermutated status with high TMB after treatment with TMZ and
another subset of patients who have germline mutations leading to hypermutated status [87–92].
Therefore, further characterization of immune abundance based on gene expression of glioblastoma
can prove to be helpful in identifying selected patients as immunotherapy continues to assume a critical
role in the treatment of cancer. The correlation between glioblastoma genetic subtypes and tumor
response to immunotherapy is an open area for research as deeper understanding is required to evaluate
the effect of molecular variations on tumor cell survival and sensitivity or resistance to immunotherapy.
2.4. Extrinsic Factors Related to the Microenvironment Modulating Effect of Previous Glioblastoma Treatments
Several iatrogenic factors can affect and lead to alteration of glioblastoma on the genomic level as
well as TME. As mentioned in the previous section, treatment with TMZ can increase hypermutated
status, which is associated with higher neoantigen formation [87–90]. In addition, TMZ which is
known to cause lymphopenia during treatment, has been shown to have an immunomodulatory effect
which could enhance anti-tumor immune response [93]. In contrast, steroids which are commonly
used in glioblastoma patients to treat tumor associated vasogenic edema and mass effect can lead to
lymphodepletion and favor a more immunosuppressive environment which could hinder efficacy
of novel drug effects such as immunotherapy [94,95]. Moreover, the use of glucocorticoids before or
during treatment with ICI in different solid tumors is associated with a decreased response and worse
OS [96]. This is of importance, as most patients with glioblastoma are treated with dexamethasone
and are expected to have a degree of persistent immunosuppression that could counteract the efficacy
of immunotherapies.
Additionally, bevacizumab which is used in the treatment of primary and recurrent glioblastoma
can lead to diminished infiltrative immune suppressive cells, low PD-1/PD-L1 expression and increased
cytotoxic T cells which can alter the efficacy of immunotherapies [97]. To this end, highlighting
the influence of previous medications on TME of glioblastoma and subsequent treatments such as
immunotherapy, is imperative when evaluating the efficacy of novel glioblastoma therapeutics [98].
3. Immunotherapy in the Treatment of Glioblastoma
Immunotherapy entails several pharmaceutical compounds that have different mechanism of
action and can be categorized into: (1) Monoclonal antibodies (ICI) that target checkpoint protein
receptors (CTLA-4, PD-1, PD-L1, TIM3, IDO, LAG3); (2) adoptive transfer of bioengineered immune
cells which are designed to destroy malignant cells such as CAR-T cell therapy and CAR-natural
killer therapy (CAR-NK); (3) cancer vaccines that use mutant tumor peptides or immune cell-based
components to induce anti-tumor immunity; and (4) oncolytic viruses that preferentially destroy
malignant cells through direct and indirect mechanisms by engaging effector immune cells against
cancer cells.
3.1. Immune Checkpoint Inhibitors in Glioblastoma
Immune checkpoint inhibitors (ICIs) have revolutionized the management of cancer in the last
decade since the approval of CTLA-4 inhibitor (ipilimumab) in 2011, which was followed by approval
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of other ICI (PD-1/PD-L1 inhibitors). As mentioned previously, ICI can reinvigorate anti-tumor immune
response by blocking checkpoint receptor molecules which are responsible for an immune-inhibitory
effect that leads to immune evasion of cancer cells. The clinical efficacy of this class of medication
has been echoed by durable improved outcomes including prolonged OS and PFS in several solid
tumors including melanoma, lung, urothelial, breast, and liver cancers. Following the successful
implementation of ICI in several solid malignancies, further research was conducted to evaluate their
efficacy in other tumor types including glioblastoma. As the main target of ICI is the checkpoint receptor
in TME, the presence of these receptors appears to be essential to enhance the ability of these drugs to
interrupt checkpoint protein interaction with the respective ligand receptor which eventually lead to
reactivation of anti-tumor response [99]. This was reflected by several clinical trials which showed that
the expression of a checkpoint receptor (PD-L1) correlated with improved outcomes in patients with
metastatic lung and urothelial cancer who received PD-1/PD-L1 inhibitors (though this correlation can
vary depending on the choice of ICI and tumor type) [100]. As such, a recent study demonstrated an
increased expression of the checkpoint receptor PD-L1 in 90% of 135 patients who were diagnosed with
glioblastoma [66]. This serves as a proof of concept of a potential role of ICI in treatment of glioblastoma
because of the presence of targetable checkpoint receptors in TME. Consequentially, the presence of
checkpoint receptors in glioblastoma appears to amplify immunosuppression and correlate with worse
prognosis. For example, a study by Nduom et al. showed that expression of PD-L1 in 94 glioblastoma
patients correlated with increased risk of death (hazards ratio [HR] = 1.54, p = 0.0343) [101]. Similarly,
high expression of other checkpoint receptors such as CTLA-4, TIM3, and IDO was found to correlate
with negative outcomes and decreased survival [70,102,103].
The enthusiasm to carry out the outstanding results achieved in cancer management with ICI,
has not been as successful as anticipated in glioblastoma trials. This was demonstrated in a pivotal
phase III randomized controlled trial (CheckMate-143), which compared the safety and efficacy of
nivolumab (PD-1 inhibitor) versus bevacizumab in patients with recurrent glioblastoma who were
previously treated with TMZ and radiotherapy at initial diagnosis [104]. This study demonstrated
a lower objective response rate, lower PFS, similar median OS, and higher treatment-related adverse
events in patients who received nivolumab compared to those who received bevacizumab [104].
Another phase-3 trial evaluating the addition of nivolumab to concurrent chemoradiation (TMZ and
radiotherapy) in newly diagnosed MGMT-unmethylated glioblastoma failed to demonstrate improved
outcomes [105]. Similarly, another PD-1 inhibitor (pembrolizumab) did not achieve improved PFS
at 6 months or improved OS in a phase II study evaluating pembrolizumab versus pembrolizumab
and bevacizumab in recurrent glioblastoma [106]. Despite the disappointing results of these clinical
trials, they provided important clues which further helped in designing new trials testing different
approaches of ICI treatment in glioblastoma.
One of the factors that is proposed to contribute to the decreased response of ICI is its inability to
reach tumor cells. This is of importance as the BBB allows passage of limited small size compounds
less than 400 Da, whereas nivolumab and pembrolizumab have a molecular weight of 146 kDA and
149 kDa respectively [107–109]. As such, there are several groups working on enhancing the delivery
of these pharmaceuticals through the BBB into the TME. Some of this work focuses on nanoparticle
delivery systems as described before [45], and other groups are investigating combining ICI with
radiotherapy to increase the disruption of BBB (ClinicalTrials.gov Identifier: NCT02311582).
Another factor that appears to be fundamental for the efficacy of ICI in treatment of glioblastoma
is the timing of administration. Most of the trials to date have examined efficacy of ICI either in the
recurrent setting or in first line setting in combination with concurrent chemoradiation after surgical
resection of the tumor. Therefore, it was tempting to evaluate the use of ICI prior to surgery as they
have demonstrated improved outcomes in the neo-adjuvant setting in different tumors such as breast
cancer and melanoma [110]. Several advantages can be achieved with neo-adjuvant administration of
ICI including higher T-cell expansion in these patients compared to those who receive ICI after surgical
resection of the tumor [111]. This is hypothesized to be the result of a large tumor bulk presence
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that contains potential high load of immunogenic antigens, which can elicit a more robust anti-tumor
response in the presence of ICI. As such, the efficacy of ICI in the post-surgical setting could attenuate
the anti-tumor immune response because of the unavailability of tumor antigens after surgical resection
of the tumor. The advantage of neo-adjuvant ICI has been validated in recurrent glioblastoma in
several studies. Cloughesy et al. randomized 35 patients with recurrent glioblastoma to receive either
neo-adjuvant pembrolizumab (one single dose intravenously 2 weeks prior to surgery) and/or adjuvant
ICI [112]. The study highlighted the role of neo-adjuvant ICI in upregulating T-cell populations
and interferon-γ-related gene expression compared to subjects who did not receive neo-adjuvant
pembrolizumab [112]. This also correlated with an observed median OS of approximately 14 months in
patients who received neo-adjuvant pembrolizumab versus 7.5 months in those who did not receive ICI
prior to surgical resection [112]. Similarly, another phase-II trial replicated similar findings in patients
with recurrent glioblastoma who received neo-adjuvant nivolumab prior to surgical resection [113].
The administration of nivolumab before surgery was associated with a higher immune cell activity in
the TME, higher tumor-infiltrating lymphocytes, and enhanced expression of chemokine transcripts,
however, this trial did not result in prolonged OS [113]. To this end, the sequence of ICI administration
in regards to surgery in glioblastoma appears to be imperative for the enhancement of the functional
immune landscape leading to a substantial tumor response and seem to be promising, which led to
several clinical trials that are ongoing to address this approach.
Furthermore, the potential role of ICI in the treatment of glioblastoma appears to be significant in
specific subpopulations. For example, tumor mutation burden (TMB) and mismatch repair deficiency
(MRD) reflect a state in which a tumor is loaded with a high number of mutated proteins and
neoantigens given the defective DNA repair mechanisms. This can convert the tumor into a hotspot as
a target for anti-tumor immunity mediated by ICI as higher number of immunogenic antigens are
expected to elicit a strong immune response [114,115]. Despite the low frequency of both TMB and MRD
in glioblastoma, some patients have been described to have defective DNA repair mechanisms leading
to an immune permissive TME, which provides an advantage for ICI in priming an anti-glioblastoma
immune response [116,117]. To illustrate this, Bouffet et al. reported a durable response with the use of
nivolumab in two pediatric siblings with recurrent glioblastoma who had biallelic MRD [92]. Similarly,
another report demonstrated a durable response to pembrolizumab in an adult patient with recurrent
glioblastoma who had germline polymerase DNA epsilon (POLE) deficiency which correlated with
a high tumor mutation load [91]. To this end, it is important to highlight that hypermutation status and
high tumor mutation burden do not confer a better response when they develop after the administration
of TMZ. This has been demonstrated in a study by Touat et al. that analyzed hypermutation and
TMB status in 10,294 gliomas and found that hypermutation status post-TMZ was associated with
lower abundance of tumor infiltrative lymphocytes and worse outcomes [118]. This highlights the
difference between the hypermutation induced by germline deficiency in DNA repair mechanisms
versus hypermutation induced by post-TMZ use. In addition, specific mutations in glioblastoma have
not been reported to be associated with improved response when treated with ICI as demonstrated
by Zhao et al. who reported increased and prolonged response to PD-1 inhibitors in glioblastoma
patients who had B-raf murine sarcoma (BRAF) and protein tyrosine phosphatase non-receptor type 11
(PTPN11)-activating mutations [84]. This collective evidence points toward more individualized trial
design and further investigation into genomic characteristics to identify potential patients who could
be candidates for ICI therapy.
Current efforts are focused on combining ICI with different treatment modalities in glioblastoma
such as the novel checkpoint inhibitors of LAG3 and TIM3 [119,120]. Interestingly, a variety of
molecules and receptors have emerged recently as potential targets in combination with ICI such as
TGF-β inhibitors, colony-stimulating factor-1 ligand (CSF-1) inhibitors, and CD47 blockade [121,122].
Other interesting approaches studying the effect of epigenetic in glioblastoma have been suggested
such as the use of micro RNA (miRNA) modulation effect on the TME as a biomarker to predict
response and resistance to ICI to guide treatment and has been reviewed [123]. The ongoing research
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on identifying selected patient population, identifying the right sequence of treatment, and combining
ICI with other investigational therapeutics seem to hold a high promise in further advancement of
glioblastoma care Figure 2.
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and combinatorial therapies. Panel ( ) demonstrates the promising approach of administering ICI
in the neo-adjuvant setting prior to surgical resection of glioblastoma and followed by adjuvant
ICI [112,113]. Convection enhanced delivery of nanoparticle ICI is another method that could improve
the availability and action of ICI in glioblastoma [44]. Panel (B) shows that proper patient selection for
treatment with ICI could be of a clinical benefit such as patients with high tumor mutation burden
due to germline deficiency affecting DNA repair mechanisms and in patients with specific mutations
that could attenuate the immunosuppressive effect in the microenvironment of the tumor [84,91,92].
Panel (C) illustrates ongoing investigational combination of ICI with other novel therapies.
3.2. Adoptive Cell Therapy in Glioblasto a
Adoptive cell therapy in cancer treatment relies on redirecting immune cells to engage with specific
tumor antigens based on bioengineered chimeric antigen receptors expressed in autologous T cells [124].
By targeting tumor antigens, bioengineered T-cells are able to initiate an augmented anti-tumor response
through the activation of a variety of effector immune cells. This approach has shown promising
results in hematological malignancies, which has generated enthusiasm toward applying this new
approach in glioblastoma especially given that there was a signal of response observed in patients
with secondary CNS lymphoma who received CAR-T therapy [125]. This therapy was initially
investigated in glioblastoma to evaluate safety due to the known severe adverse event of immune
effector-associated neurological syndrome (ICANS) which can increase toxicity and morbidities in
glioblastoma patients who already have neurologic deficits. To this end, Brown et al. reported the safety
of administering CAR IL13Rα2 expressed on cytotoxic T-lymphocyte clones in patients with recurrent
glioblastoma [126]. The latter work has led to a report of a significant clinical response in a patient
with recurrent glioblastoma who was treated with IL13BBζ–CAR T cells with sustained disease control
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that lasted 7.5 months but later progressed to four different new locations [127]. Other investigators
explored targeting different glioblastoma-related tumor cell receptors such as epidermal growth
factor receptor variant-III (EGFRvIII) and human epidermal receptor-2 (HER2) as they are commonly
expressed on glioblastoma cells. These studies demonstrated safety of EGFRvIII-CAR and HER2-
CAR-T infusions and an active anti-tumor effect, however, this was yet to demonstrate a clinical benefit
with an improved survival [128–130]. Another approach of adoptive cell therapy that has just entered
early clinical investigation involves the administration of bioengineered NK cells [131]. The advantage
of using NK cells compared to CAR-T cell therapy relies on the fact that NK cells are leveraged to retain
high cytotoxic effect against tumor cells irrespective of specific antigen expression which could lead to
an increased efficacy against antigenically heterogeneous tumor cells [131]. Nevertheless, the immature
results of CAR-cell-based therapy in glioblastoma require further evidence and investigation to support
safety and efficacy in glioblastoma. Among the important factors to address during the ongoing
research on CAR-cell therapy in glioblastoma include: finding a common targetable antigen that is
universally expressed on tumor cells and is involved in driving tumorigenesis, expanding the repertoire
of the bioengineered cells to target more than one antigen such as using bi-specific CAR-T-cell therapy
and acceptable safety [132].
3.3. Therapeutic Vaccine Therapy in Glioblastoma
Therapeutic cancer vaccination relies on the method of inducing an anti-tumor immune response
by selecting tumor-associated antigens or mutated peptides that are specific for cancer cells and are not
universally expressed in healthy tissue. These candidate antigens are then either enhanced ex vivo or
incubated in specific immune cells like dendritic cells and then reintroduced into the patient. By doing
so, immunogenic tumor-associated antigens are hypothesized to initiate a tumor-specific immune
response that can contribute to regression of malignant cells [133]. The platform of therapeutic vaccines
in glioblastoma utilizes different approaches and can be classified into: (a) Tumor antigen associated
vaccines that use commonly expressed oncogene-derived proteins on tumor cell surface such as the use
of EGFRvIII and IDH1(R132H) to elicit a specific immune response; (b) vaccines that use heat shock
protein family to illicit an immune response against a variety of different tumor antigens; (c) cell-based
vaccine using autologous or allogenic dendritic cell (DC) which serves in initiating anti-tumor response
through enhanced antigen presentation and; (d) personalized vaccines using immunogenomic methods
to detect patient-specific novel peptides which are considered to be immunogenic neoantigen to
enhance the response against malignant cells.
Vaccine-based therapies using EGFRvIII have generated a lot of enthusiasm as extracellular
mutations of EGFRvIII are commonly expressed in glioblastoma (approximately 20%) and are
responsible for constitutive EGFR pathway activation [134]. Early phase-II clinical trial conducted
by Schuster et al. demonstrated safety and increased immunogenicity of EGFRvIII peptide sequence
conjugated to keyhole limpet hemocyanin when administered with Stupp protocol in newly diagnosed
glioblastoma [135]. However, despite the early encouraging results, a phase-III randomized controlled
trial failed to demonstrate survival advantage of the candidate vaccine [136]. Interestingly, a signal
of clinical benefit was observed in the previous trial when a post-hoc analysis showed improved OS
in patients with bulky glioblastoma who received the vaccines although this was not the primary
end point of the study [136]. In addition, a recent randomized phase-II trial demonstrated improved
PFS in patients with EGFRvIII-positive recurrent glioblastoma when they received EGFRvIII vaccine
in combination with bevacizumab versus those receiving placebo-bevacizumab [137]. To this end,
EGFRvIII vaccines could assume a future role in the treatment of glioblastoma based on an enhanced
clinical signal observed in specific subpopulations or when the vaccine is used in combination with other
treatment modalities, although further confirmatory large randomized trials will be needed. Another,
potential mutated protein that is commonly encountered in glioblastoma and has been shown to induce
immunogenicity is IDH1 R132H [138]. Early results demonstrated safety and immunogenicity of
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a vaccine targeting this mutation in a German phase I clinical trial in 32 patients with newly diagnosed
IDH1 R132H mutant malignant astrocytoma [139].
While vaccines against EGFRvIII and IDH1 R132H target specifically malignant cells that express
the mutant protein, vaccination using heat shock protein family can leverage a broader response
targeting a variety of tumor antigens in glioblastoma which could mitigate the heterogeneous nature
of the tumor as a resistance mechanism. This is hypothesized to be the result of the function of heat
shock protein family in post translational protein processes and presentation of antigens on MHC
class I [140]. Several groups have demonstrated relative safety and immunogenicity using heat shock
protein family vaccines in newly diagnosed and recurrent glioblastoma but data is still immature to
support their clinical utility [141–143].
The rationale of using DC vaccines stems from their unique characteristics as highly potent cells
that have the capacity to present antigens. The presentation of antigens by DC leads to sensitization of
naïve T cells and priming of an anti-tumor immune response. The potential benefit of dendritic cell
vaccination in newly diagnosed and recurrent glioblastoma has been illustrated in a systematic review
that included a total of 403 patients and showed improved OS in patients with glioblastoma who
received DC vaccines compared to historical average survival [144]. A randomized phase-III trial by
Liau et al. have further corroborated the evidence of a benefit with the addition of autologous tumor
lysate-pulsed DC vaccine (DCVax-L) to Stupp protocol in patients with newly diagnosed glioblastoma
which has led to the approval of this vaccine in Switzerland [145].
Finally, personalized vaccines using newly detected neoantigens is another promising avenue in
glioblastoma research. This personalized vaccine approach is based on the fact that neoantigens are
composed of immunogenic-mutated peptides that are the product of genomic disruption in glioblastoma
cells and when expressed in the TME can lead to an anti-tumor response [146]. For example, the use
of personalized vaccine composed of DCVax followed by a neoantigen-based synthetic long peptide
vaccine demonstrated immunogenicity of such an approach in a patient with newly diagnosed
glioblastoma [147]. Of interest, two recent clinical trials have further demonstrated the immunogenic
potential and clinical efficacy using whole-exome sequencing or microarray analysis in identifying
candidate neoantigen peptide vaccines that were shown to generate anti-tumor response [148,149].
Key challenges remain when developing therapeutic glioblastoma vaccines including heterogeneity
of glioblastoma as well as the immunosuppressive environment, which constitute a major hurdle given
their direct dependency on antigen-specific derived immune response. The ongoing work evaluating
variable vaccines in glioblastoma treatment should offer further insight.
3.4. Oncolytic Virus Therapy
Oncolytic viral therapy in glioblastoma involves the intratumoral administration of genetically
modified viruses that usually have neural tropism and an ability to selectively replicate inside
malignant infected cells. The amplified replication of lytic viruses leads to the destruction of the
target cell and further propagation of viral progeny in addition to intracellular molecules, which can
induce and augment anti-tumor immune response [150,151]. Some tumor-selective lytic viruses
have shown ability to replicate in glioma cells and are currently being studied in early phase clinical
trials including herpes simplex virus (HSV), adenovirus, poliovirus, gamma-retrovirus, and zika
virus [150,152,153]. The method of administration is by intraparenchymal or intracranial arterial
convection-enhanced delivery which allows for the direct intratumoral administration of the oncolytic
virus. Although the majority of the results of this therapeutic avenue remains confined to early phase
clinical trials, the results to date have demonstrated accepted safety and efficacy of this approach.
For example, Ji et al. reported the results of administration of intra-arterial cerebral infusion of
adenovirus mutant thymidine kinase in 53 patients with recurrent glioblastoma and showed improved
PFS and OS compared to control group [154]. This study demonstrated acceptable safety compared to
control groups with the exception of one patient who developed vasospasm 10 days after oncolytic
viral administration [154]. Similarly, Cloughesy et al. demonstrated tolerability of using retroviral
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replicating virus (Toca511) followed by administration of Toca FC which led to the preferential killing
of infected cancer cells through delivery of a yeast cytosine deaminase, which in turn converts
5-fluorocytosine to 5-fluorouracil (a chemotherapeutic compound that inhibits tumor cell growth and
leads to cytotoxicity) [155]. In this phase I, open-label trial, 45 patients with recurrent glioblastoma
received the viral therapy. The trials demonstrated the safety of this approach and an OS survival
benefit although it was not the primary endpoint of this study [155]. As mentioned previously,
Desjardins et al. demonstrated safety and significant OS improvement in patients with recurrent
glioblastoma who received a recombinant oncolytic polio-rhinovirus (PVSRIPO) with an OS rate
of 21% at 24 months which was maintained at 36 months [48]. The promising efficacy of oncolytic
viral therapy in glioblastoma treatment led to FDA breakthrough designation for PVSRIPO in 2016.
Recently, the overall survival rate at 36 months from Desjardins group (OS rate of 20%) was replicated
by Lang et al. who administered an oncolytic-replicating adenovirus (DNX-2401) in 25 patients
with recurrent glioblastoma [156]. Interestingly, it was observed that there was a decrease in the
exhaustion of TIM3 and increased infiltration by CD8+ T cells of tumor specimens after the treatment
with the oncolytic vaccine which has led to another clinical trial evaluating the combination of this
vaccine with PD-1 inhibitor (NCT02798406). This cumulative evidence opens a new avenue for the
immunotherapies in glioblastoma although it is essential to confirm the previous findings in large
phase 3 randomized trials.
4. Targeted Therapies in Glioblastoma
The advent of molecular targeted therapy has revamped cancer treatment since their introduction
in early 2000. Their efficacy relies on targeting specific molecular alterations or their protein products
which govern malignant cell growth and enhance the invasive nature of the tumor. Most of the targeted
therapies are tyrosine kinase inhibitors (TKIs) that can prevent kinase phosphorylation which are
implicated in cancer cell proliferation and angiogenesis [157]. Conversely, drugs that can block receptors
in the TME involved in tumor growth such as VEGF inhibitors are considered targeted therapies.
The successful use of these targeted therapies in multiple solid and hematological malignancies has
persuaded the investigation of their efficacy in glioblastoma. To this point, glioblastoma can be
associated with a variety of mutations which has been described by The Cancer Genome Atlas research
network [134]. This has resulted in several investigations which have been conducted to evaluate the
outcomes in glioblastoma patients treated with specific molecular targets. Variable drugs have been
investigated and were directed against mutations involving EGFR, fibroblast growth factor receptor
(FGFR), MET, BRAF-MAPK, PI3K-AKT mTOR pathway, VEGF, and integrins Figure 3.
Frequency of EGFR amplification is estimated to reach 40%, and in-frame deletions (EGFRvIII)
in approximately 25% [134]. The alterations in EGFR can lead to constitutive activation of cell
proliferation and contribute to prognosis which makes it a plausible target in specific tumors such
as breast and lung cancer. However, it appears that EGFR-associated alterations in glioblastoma
lack prognostic significance, which is multifactorial because of the difference in structural mutation
location (extracellular in glioblastoma versus intracellular in lung cancer) as well as the presence of
regulatory downstream circuits that can lead to cell growth independent of EGFR status [158,159].
As such, majority of clinical trials failed to demonstrate improved PFS or OS in recurrent patients
treated with different EGFR inhibitors including erlotinib, gefitinib, afatinib, and dacomitinib [160–163].
The failure of the previous therapeutics has shifted the focus toward different strategies using EGFR
receptors as binding sites on the tumor cells for the delivery of cytotoxic payload. Lassman et al.
demonstrated safety in 60 patients with recurrent glioblastoma who received the antibody–drug
conjugate depatuxizumab mafodotin (depatux-m) [164]. However, a more recent phase-II trial using
depatux-m in combination with TMZ at progression did not improve OS significantly compared to the
control arm [165].
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The presence of FGFR gene fusion was investigated as a target for therapy despite its low frequency
(3.5%) in glioblastoma which is exclusive to IDH1/2 wild-type tumors [166]. In the previous study,
two patients with FGFR fusion gene were treated with erdafitinib (FGFR inhibitor), and showed
promising tumor response but both eventually had progressive disease [166]. Similarly, targeting
c-MET overexpression (frequency of 13% in glioblastoma) and amplification (5%) with two phase II
trials in recurrent glioblastoma, failed to demonstrate improved outcomes [167–169].
Targeting the PI3K-AKT-mTOR pathway which is universally altered in glioblastoma has also
been unsuccessful and showed no improved outcomes in both newly diagnosed and recurrent
glioblastoma using PI3K inhibitors and mTOR inhibitors [170–172]. Interestingly, despite the low
frequency of BRAFV600E mutation in glioblastoma (up to 3%), some subtypes of glioblastoma such
as epithelioid glioblastoma show high frequency reaching 50% [173,174]. Based on the efficacy of
targeting mutations in the MAPK pathway including BRAFV600E in melanoma, several anecdotal
reports described rapid and durable anti-tumor respo se using inhibitor of this pathways such as
BRAF and MEK inhibitors [175,176]. A study b Kal y et al. has furt er corrobor t he effic c of
BRAF inhibitors in glioblastoma patients [177]. Nevertheless, utility and access to these medications
remain scarce given that most of the patients eventually develop progressive disease while on treatment
and becaus of the restricted number of eligible patients with such mutation.
Finally, other study groups attempted targeting receptors in the TME of glioblastoma which are
not necessarily expressed on tumor cells such as VEGF and integrins. The trials using the anti-VEGF
(bevacizumab) later led to its approval in the treatment of glioblastoma as described earlier in the
introduction. Several trials evaluated the efficacy of several integrin inhibitors but failed to show any
benefit of the addition of these targeted therapies and have been summarized in detail by Le Rhun et al. [178].
Collectively, the failure of most targeted therapy trials to date in treatment of glioblastoma has
resulted in the decline in the interest of targeted molecular therapy with the exception of novel
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molecular targets that are under active research [178]. Supplementary research remains essential
to identify pathways and molecular alterations that control tumor survival and resistant nature of
glioblastoma in order to develop further effective therapeutics.
5. Future Perspective of Glioblastoma Research
Despite the increased armamentarium of effective cancer therapeutics across multiple tumor
types, management of glioblastoma continues to prove the unmet need for further research to develop
new effective medication, which is echoed by the high number of clinical trials that are under way
(470 clinical trials registered at clinicaltrials.gov as of October 2020). Phase 3 randomized clinical trials
are crucial for evaluating the role of novel therapies in glioblastoma despite the promising results of
early phase clinical trials.
Addressing the immunological landscape and the crosstalk between intracranial glioblastoma
and the extracranial immune components appear to be of a high priority given that most of the
concentration revolves around exploiting the immune system against glioblastoma. Achieving clarity
on the utility of immunotherapy (ICI) up-front in the neo-adjuvant setting is promising but requires
further validation in large prospective randomized trials. In addition, several proposed approaches
have been suggested to overcome the immunosuppressive TME in glioblastoma and are currently
under investigation (summarized in Table 1).
Table 1. Factors implicated in the immunosuppressive environment of glioblastoma and possible
solutions to enhance response.
Factors Related to Glioblastoma Possible Solutions Reference
Restricted drug delivery due to blood
brain barrier
Convection enhanced delivery (CED)
and nano particles.
Disruption of blood brain barrier with
radiation therapy combined with
immune checkpoint inhibitors
Adoptive cell therapy
[44,45]
[121]
[127,128]
Effector T-cell suppression and peripheral
T-cell entrapment
Use of immune checkpoint inhibitors,
therapeutic vaccines or adoptive cell
transfer therapy
[52–55]
Increased expression of
checkpoint receptors
Use of combination checkpoint
inhibitors targeting several
checkpoint receptors
[64–70,121]
Suppression of natural killer cells Use of checkpoint inhibitorsNatural killer cell adoptive transfer [131]
Abundance of tumor associated
macrophages (TAM)
(protumorigenic phenotype)
Boosting host immunity through
exploiting plasticity in TAM to express
inflammatory phenotype M1
[73]
Increased secretion of TGF-β Use of checkpoint inhibitors withTGF-β inhibitors [121]
Furthermore, combinatorial therapies with immunotherapies is currently being explored and
appear to be promising. For example, inclusion of poly-ADP ribose polymerase (PARP) inhibitors
which induces synthetic lethality and leads to overload with defective DNA repair mechanisms
appears to be promising. Preclinical studies suggest that PARP inhibition with drugs such as olaparib
can increase neoantigen formation, lead to PD-L1 upregulation, boost type I Interferon signaling,
and reprogram TME to facilitate anti-tumor response when using ICI [179]. In addition, PARP inhibition
is thought to cause catastrophic DNA damage which may also lead to resensitized tumor cells to TMZ
in MRD glioblastoma [180]. Similarly, Hanna et al. demonstrated in a phase I trial the radio-sensitizing
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effect and the safety of olaparib administration with TMZ prior to surgery in patients with recurrent
glioblastoma [181].
Ultimately, as immunotherapy continues to dominate the research arena in glioblastoma
therapeutic development, it would be important to stratify patients based on their previous
glucocorticoid use as most of the patients require to be on steroids which is implicated in suppression
of the immune system and can counteract the effect of drugs targeting the immune system.
6. Conclusions
The lack of drug approvals for the treatment of glioblastoma and the mild to modest improvement
in survival in the past decade represent a growing need for well-designed research to develop
effective therapeutics. The ongoing effort should consider the factors that are implicated in the
resistance observed with these novel investigational therapeutics to further leverage our understanding
and optimize our treatment approach. Immunotherapy holds a promise in glioblastoma despite the
immunosuppressive nature of the tumor. Combination immunotherapy with other treatment modalities,
investigational novel compounds, and innovative delivery modalities such as antibody–drug conjugates,
convection-enhanced delivery, and nanoparticles are currently under ongoing research which will
address their safety and efficacy in glioblastoma. Further characterization of patients’ tumor molecular
profiles can help identify subpopulations who could derive a benefit from currently available treatments.
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Grochowski, C. Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints
Controllers and Sensitive Biomarkers in Glioblastoma Multiforme. Int. J. Mol. Sci. 2020, 21, 1507. [CrossRef]
124. June, C.H.; Riddell, S.R.; Schumacher, T.N. Adoptive cellular therapy: A race to the finish line. Sci. Transl. Med.
2015, 7, 280ps7. [CrossRef] [PubMed]
125. Frigault, M.J.; Dietrich, J.; Martinez-Lage, M.; Leick, M.; Choi, B.D.; DeFilipp, Z.; Chen, Y.-B.; Abramson, J.;
Crombie, J.; Armand, P.; et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood 2019,
134, 860–866. [CrossRef] [PubMed]
126. Brown, C.E.; Badie, B.; Barish, M.E.; Weng, L.; Ostberg, J.R.; Chang, W.-C.; Naranjo, A.; Starr, R.; Wagner, J.R.;
Wright, C.; et al. Bioactivity and safety of IL13Rα2-Redirected chimeric antigen receptor CD8+ T cells in
patients with recurrent glioblastoma. Clin. Cancer Res. 2015, 21, 4062–4072. [CrossRef] [PubMed]
127. Brown, C.E.; Alizadeh, D.; Starr, R.; Weng, L.; Wagner, J.R.; Naranjo, A.; Ostberg, J.R.; Blanchard, M.S.;
Kilpatrick, J.; Simpson, J.; et al. Regression of glioblastoma after chimeric antigen receptor T-Cell therapy.
N. Engl. J. Med. 2016, 375, 2561–2569. [CrossRef] [PubMed]
128. O’Rourke, D.M.; Nasrallah, M.P.; Desai, A.; Melenhorst, J.J.; Mansfield, K.; Morrissette, J.J.D.; Martinez-Lage, M.;
Brem, S.; Maloney, E.; Shen, A.; et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells
mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med.
2017, 9, eaaa0984. [CrossRef] [PubMed]
129. Ahmed, N.; Salsman, V.S.; Kew, Y.; Shaffer, D.; Powell, S.; Zhang, Y.J.; Grossman, R.G.; Heslop, H.E.;
Gottschalk, S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous
experimental tumors. Clin. Cancer Res. 2010, 16, 474–485. [CrossRef] [PubMed]
130. Ahmed, N.; Brawley, V.; Hegde, M.; Bielamowicz, K.; Kalra, M.; Landi, D.; Robertson, C.; Gray, T.L.; Diouf, O.;
Wakefield, A.; et al. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive
Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017, 3, 1094–1101. [CrossRef]
131. Burger, M.C.; Zhang, C.; Harter, P.N.; Romanski, A.; Strassheimer, F.; Senft, C.; Tonn, T.; Steinbach, J.P.;
Wels, W.S. CAR-Engineered NK cells for the treatment of glioblastoma: Turning innate effectors into precision
tools for cancer immunotherapy. Front. Immunol. 2019, 10, 2683. [CrossRef]
132. Choi, B.D.; Yu, X.; Castano, A.P.; Darr, H.; Henderson, D.B.; Bouffard, A.A.; Larson, R.C.; Scarfò, I.; Bailey, S.R.;
Gerhard, G.M.; et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells
in a preclinical model of human glioblastoma. J. Immunother. Cancer 2019, 7, 304. [CrossRef]
133. Schlom, J.; Hodge, J.W.; Palena, C.; Tsang, K.-Y.; Jochems, C.; Greiner, J.W.; Farsaci, B.; Madan, R.A.;
Heery, C.R.; Gulley, J.L. Therapeutic cancer vaccines. Adv. Cancer Res. 2014, 121, 67–124. [CrossRef]
134. Brennan, C.W.; Verhaak, R.G.W.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.;
Chakravarty, D.; Sanborn, J.Z.; Berman, S.H.; et al. The somatic genomic landscape of glioblastoma. Cell
2013, 155, 462–477, Erratum in 2014, 157, 753. [CrossRef] [PubMed]
135. Schuster, J.; Lai, R.K.; Recht, L.D.; Reardon, D.A.; Paleologos, N.A.; Groves, M.D.; Mrugala, M.M.; Jensen, R.;
Baehring, J.M.; Sloan, A.; et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed
glioblastoma: The ACT III study. Neuro-Oncology 2015, 17, 854–861. [CrossRef] [PubMed]
136. Weller, M.; Butowski, N.; Tran, D.D.; Recht, L.D.; Lim, M.; Hirte, H.; Ashby, L.; Mechtler, L.; A Goldlust, S.;
Iwamoto, F.; et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing
glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017, 18,
1373–1385. [CrossRef]
Pharmaceuticals 2020, 13, 389 24 of 26
137. Reardon, D.A.; Desjardins, A.; Vredenburgh, J.J.; O’Rourke, D.M.; Tran, D.D.; Fink, K.L.; Nabors, L.B.; Li, G.;
Bota, D.A.; Lukas, R.V.; et al. Rindopepimut with Bevacizumab for patients with relapsed EGFRvIII-Expressing
Glioblastoma (ReACT): Results of a double-blind randomized phase II trial. Clin. Cancer Res. 2020, 26, 1586–1594.
[CrossRef]
138. Schumacher, T.; Bunse, L.; Pusch, S.; Sahm, F.; Wiestler, B.; Quandt, J.; Menn, O.; Osswald, M.; Oezen, I.;
Ott, M.; et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014, 512, 324–327.
[CrossRef]
139. Platten, M.; Schilling, D.; Bunse, L.; Wick, A.; Bunse, T.; Riehl, D.; Green, E.; Sanghvi, K.;
Karapanagiotou-Schenkel, I.; Harting, I.; et al. ATIM-33. NOA-16: A first-in-man multicenter phase
i clinical trial of the german neurooncology working group evaluating a mutation-specific peptide vaccine
targeting idh1r132h in patients with newly diagnosed malignant astrocytomas. Neuro-Oncology 2018, 20
(Suppl. 6), vi8–vi9. [CrossRef]
140. Ampie, L.; Choy, W.; Lamano, J.B.; Fakurnejad, S.; Bloch, O.; Parsa, A.T. Heat shock protein vaccines against
glioblastoma: From bench to bedside. J. Neurooncol. 2015, 123, 441–448. [CrossRef]
141. Crane, C.A.; Han, S.J.; Ahn, B.; Oehlke, J.; Kivett, V.; Fedoroff, A.; Butowski, N.; Chang, S.M.; Clarke, J.;
Berger, M.S.; et al. Individual patient-specific immunity against high-grade glioma after vaccination with
autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin. Cancer Res. 2013, 19, 205–214.
[CrossRef]
142. Bloch, O.; Crane, C.A.; Fuks, Y.; Kaur, R.; Aghi, M.K.; Berger, M.S.; Butowski, N.A.; Chang, S.M.; Clarke, J.L.;
McDermott, M.W.; et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma:
A phase II, single-arm trial. Neuro-Oncology 2014, 16, 274–279. [CrossRef]
143. Ji, N.; Zhang, Y.; Liu, Y.; Xie, J.; Wang, Y.; Hao, S.; Gao, Z. Heat shock protein peptide complex-96 vaccination
for newly diagnosed glioblastoma: A phase I, single-arm trial. JCI Insight 2018, 3, e99145. [CrossRef]
144. Bregy, A.; Wong, T.M.; Shah, A.H.; Goldberg, J.M.; Komotar, R.J. Active immunotherapy using dendritic cells
in the treatment of glioblastoma multiforme. Cancer Treat. Rev. 2013, 39, 891–907. [CrossRef] [PubMed]
145. Liau, L.M.; Ashkan, K.; Tran, D.D.; Campian, J.L.; Trusheim, J.E.; Cobbs, C.; Heth, J.A.; Salacz, M.; Taylor, S.;
D’Andre, S.D.; et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell
vaccine in newly diagnosed glioblastoma. J. Transl. Med. 2018, 16, 142, Erratum in 2018, 16, 179. [CrossRef]
[PubMed]
146. Richters, M.M.; Xia, H.; Campbell, K.M.; Gillanders, W.E.; Griffith, O.L.; Griffith, M. Best practices for
bioinformatic characterization of neoantigens for clinical utility. Genome Med. 2019, 11, 56. [CrossRef]
147. Johanns, T.M.; Miller, C.A.; Liu, C.J.; Perrin, R.J.; Bender, D.; Kobayashi, D.K.; Campian, J.L.; Chicoine, M.R.;
Dacey, R.G.; Huang, J.; et al. Detection of neoantigen-specific T cells following a personalized vaccine in
a patient with glioblastoma. OncoImmunology 2019, 8, e1561106. [CrossRef] [PubMed]
148. Hilf, N.; Kuttruff-Coqui, S.; Frenzel, K.; Bukur, V.; Stevanović, S.; Gouttefangeas, C.; Platten, M.; Tabatabai, G.;
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